Bayer says its experimental blood thinner cuts risk and severity of repeat strokes
Published on May 6, 2026.
Bayer (Bayer) has announced that its experimental blood thinner, asundexian, has reduced the incidence and severity of these strokes in a phase III trial, with 6.2% of these incidents compared to 8.4% in patients who had previously experienced a non-ancient stroke or a high-profile high-ranking high-level of uncertainty. The company also revealed that its new drug is effective in reducing the risk of these episodes.
Related Articles
Fresno business owner says thieves ransacked her nail salon, took thousands in supplies
A Fresno nail salon owner was devastated by a pre-planned burglary that cost her $5,000 to replace lost tools and supplies.
Delano businesses go bananas for record-breaking attendance
The historic Banana Ball event in Wichita has led to record-breaking attendance, boosting local business and creating special menus for visitors.
College Success Speaks LLC - Alsip, IL Patch
I work with parents and students to provide clarity and confidence in college costs, offering comprehensive guidance on FAFSA and other financial aid options.